Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Фаза 3
Идёт, набор закрыт
NCT00644228
| Заболевание | DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | National Cancer Institute (NCI) |
|---|
| Статус | Идёт, набор закрыт |
|---|
| Участники | 525 участн. |
|---|
| Вмешательство | Bortezomib, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide |
|---|
| Дата начала | 28.07.2008 |
|---|
| Дата завершения | 5.11.2015 |
|---|
| Публикация результатов | 6.07.2017 |
|---|
Кратко
This randomized phase III trial studies lenalidomide, dexamethasone, and bortezomib to see how well it works compared to dexamethasone and lenalidomide alone in treating patients with previously untreated multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the cancer. It is not yet known whether lenalidomide and dexamethasone is more effective with or without bortezomib in treating multiple myeloma.
Progression-free Survival
From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 6 years · Months
| Arm I (Dexamethasone and Lenalidomide) | 30 Months |
|---|
| Arm II (Dexamethasone, Lenalidomide, Bortezomib) | 43 Months |
|---|
| p-value | 0.0018 |
| Hazard Ratio (HR) | 0.712 (95% CI 0.560–0.906) |
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.